Alzheimer's disease: From pathogenesis to novel therapeutic approaches

Research output: Contribution to journalArticle

Abstract

The two major neuropathologic hallmarks of Alzheimer's disease are extracellular amyloid β (Aβ) plaques and intracellular neurofibrillary tangles. Several additional pathogenic mechanisms have been described, including inflammation, oxidative damage, ion disregulation and cholesterol metabolism. A number of compounds have been developed, trying to interfere with the above-mentioned mechanisms. These drugs are supposed to modify pathological steps leading to Alzheimer's disease, thus acting on the evolution of the disease. Some of these compounds are under clinical testing, others are in preclinical phases of development. In this review, the main pathogenic steps leading to neurodegeneration will be discussed, together with an update on potentially disease-modifying drugs under testing.

Original languageEnglish
Pages (from-to)259-277
Number of pages19
JournalTherapy
Volume6
Issue number2
DOIs
Publication statusPublished - Mar 2009

Fingerprint

Alzheimer Disease
Neurofibrillary Tangles
Amyloid Plaques
Pharmaceutical Preparations
Cholesterol
Ions
Inflammation
Therapeutics

Keywords

  • Alzheimer's disease
  • Amyloid
  • Anti-inflammatories
  • Disease-modifying drugs
  • Inflammation
  • Tau

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

Alzheimer's disease : From pathogenesis to novel therapeutic approaches. / Scarpini, Elio; Galimberti, Daniela.

In: Therapy, Vol. 6, No. 2, 03.2009, p. 259-277.

Research output: Contribution to journalArticle

@article{4d2fc326692043ed84e31333ba9b9cb5,
title = "Alzheimer's disease: From pathogenesis to novel therapeutic approaches",
abstract = "The two major neuropathologic hallmarks of Alzheimer's disease are extracellular amyloid β (Aβ) plaques and intracellular neurofibrillary tangles. Several additional pathogenic mechanisms have been described, including inflammation, oxidative damage, ion disregulation and cholesterol metabolism. A number of compounds have been developed, trying to interfere with the above-mentioned mechanisms. These drugs are supposed to modify pathological steps leading to Alzheimer's disease, thus acting on the evolution of the disease. Some of these compounds are under clinical testing, others are in preclinical phases of development. In this review, the main pathogenic steps leading to neurodegeneration will be discussed, together with an update on potentially disease-modifying drugs under testing.",
keywords = "Alzheimer's disease, Amyloid, Anti-inflammatories, Disease-modifying drugs, Inflammation, Tau",
author = "Elio Scarpini and Daniela Galimberti",
year = "2009",
month = "3",
doi = "10.2217/14750708.6.2.259",
language = "English",
volume = "6",
pages = "259--277",
journal = "Therapy",
issn = "1475-0708",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Alzheimer's disease

T2 - From pathogenesis to novel therapeutic approaches

AU - Scarpini, Elio

AU - Galimberti, Daniela

PY - 2009/3

Y1 - 2009/3

N2 - The two major neuropathologic hallmarks of Alzheimer's disease are extracellular amyloid β (Aβ) plaques and intracellular neurofibrillary tangles. Several additional pathogenic mechanisms have been described, including inflammation, oxidative damage, ion disregulation and cholesterol metabolism. A number of compounds have been developed, trying to interfere with the above-mentioned mechanisms. These drugs are supposed to modify pathological steps leading to Alzheimer's disease, thus acting on the evolution of the disease. Some of these compounds are under clinical testing, others are in preclinical phases of development. In this review, the main pathogenic steps leading to neurodegeneration will be discussed, together with an update on potentially disease-modifying drugs under testing.

AB - The two major neuropathologic hallmarks of Alzheimer's disease are extracellular amyloid β (Aβ) plaques and intracellular neurofibrillary tangles. Several additional pathogenic mechanisms have been described, including inflammation, oxidative damage, ion disregulation and cholesterol metabolism. A number of compounds have been developed, trying to interfere with the above-mentioned mechanisms. These drugs are supposed to modify pathological steps leading to Alzheimer's disease, thus acting on the evolution of the disease. Some of these compounds are under clinical testing, others are in preclinical phases of development. In this review, the main pathogenic steps leading to neurodegeneration will be discussed, together with an update on potentially disease-modifying drugs under testing.

KW - Alzheimer's disease

KW - Amyloid

KW - Anti-inflammatories

KW - Disease-modifying drugs

KW - Inflammation

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=69449086846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69449086846&partnerID=8YFLogxK

U2 - 10.2217/14750708.6.2.259

DO - 10.2217/14750708.6.2.259

M3 - Article

AN - SCOPUS:69449086846

VL - 6

SP - 259

EP - 277

JO - Therapy

JF - Therapy

SN - 1475-0708

IS - 2

ER -